|
|
||||||||||
|
J Am Coll Cardiol, 2002; 39:1518-1523 © 2002 by the American College of Cardiology Foundation |



,*
* Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA
Clinical Chemistry Laboratories, Massachusetts General Hospital, Boston, Massachusetts, USA
Cardiac Surgery Division, Massachusetts General Hospital, Boston, Massachusetts, USA
Manuscript received September 6, 2001; revised manuscript received January 30, 2002, accepted February 6, 2002.
* Reprint requests and correspondence: Dr. Elizabeth Lee-Lewandrowski, Clinical Chemistry Laboratories, Massachusetts General Hospital, Gray-Bigelow 5, 55 Fruit Street, Boston, Massachusetts 02114, USA.
ELewandrowski{at}Partners.org
OBJECTIVES: The aim of this study was to assess the role of serum markers of myocardial necrosis after cardiac surgery.
BACKGROUND: The role of serum troponin T (TnT) and creatine kinase-MB (CK-MB) for the risk stratification of patients after cardiac surgery remains undefined.
METHODS: Serum levels of TnT and CK-MB were measured from 224 patients every 8 h after cardiac surgery. The results of serum cardiac marker testing were correlated with adverse events, including new myocardial infarction (MI), cardiogenic shock or death. Univariable analysis identified factors predictive of complications, while stepwise logistic regression identified independent predictors of postoperative complications.
RESULTS: Cardiac marker elevation was universal after cardiac surgery. At all time points measured, compared with those patients without complications, the TnT levels from patients with complications were more significantly elevated (all: p < 0.0005). In contrast, among identically timed specimens, the levels of CK-MB from complicated patients were less reliably discriminatory. Multivariable analysis suggested that a TnT level in the highest quintile (
1.58 ng/ml) was the strongest predictor of complications, including death (post-op, odds ratio [OR] = 31.0, 95% confidence interval [CI] = 3.67 to 263.1, p = 0.002) or shock (post-op: OR = 18.9, 95% CI = 2.29 to 156.1, p = 0.006; 18 h to 24 h: OR = 30.7, 95% CI = 3.75 to 250.7, p = 0.001), as well as the composite end points of death/MI (18 h to 24 h: OR = 60.1, 95% CI = 7.34 to 492.1, p < 0.0005), shock/MI (post-op: OR = 23.3, 95% CI = 2.82 to 191.4, p = 0.003; 18 h to 24 h: OR = 37.8, 95% CI = 4.66 to 307.3, p = 0.001) or death/shock/MI (post-op: OR = 20.0, 95% CI = 2.81 to 142.0, p = 0.003; 18 h to 24 h: OR = 67.4, 95% CI = 6.96 to 652.3, p < 0.0005). In contrast, in the presence of TnT, the results of CK-MB measurement added no independent prognostic information.
CONCLUSIONS: Troponin T is superior to CK-MB for the prediction of impending complications after cardiac surgical procedures.
| ||||||||||||||||
This article has been cited by other articles:
![]() |
A. S. Jaffe Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers Clin. Chem., September 1, 2008; 54(9): 1432 - 1442. [Abstract] [Full Text] [PDF] |
||||
![]() |
NACB WRITING GROUP MEMBERS, A. H.B. Wu, A. S. Jaffe, F. S. Apple, R. L. Jesse, G. L. Francis, D. A. Morrow, L. K. Newby, J. Ravkilde, W.H. W. Tang, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure Clin. Chem., December 1, 2007; 53(12): 2086 - 2096. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Thygesen, J. S. Alpert, H. D. White, and on behalf of the Joint ESC/ACCF/AHA/WHF Task Force Universal Definition of Myocardial Infarction J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2173 - 2195. [Full Text] [PDF] |
||||
![]() |
K. Thygesen, J. S. Alpert, H. D. White, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force, TASK FORCE MEMBERS: Chairpersons: Kristian Thygese, Biomarker Group: Allan S. Jaffe, Coordinator (USA), ECG Group: Bernard Chaitman, Co-ordinator (USA), P, Imaging Group: Richard Underwood, Coordinator (UK), Intervention Group: Jean-Pierre Bassand, Co-ordina, Clinical Investigation Group: Paul W. Armstrong, C, et al. Universal Definition of Myocardial Infarction Circulation, November 27, 2007; 116(22): 2634 - 2653. [Full Text] [PDF] |
||||
![]() |
Task Force Members, K. Thygesen, J. S. Alpert, H. D. White, Biomarker Group, A. S. Jaffe, F. S. Apple, M. Galvani, H. A. Katus, L. K. Newby, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Eur. Heart J., October 2, 2007; 28(20): 2525 - 2538. [Full Text] [PDF] |
||||
![]() |
O. J. Liakopoulos, J. D. Schmitto, S. Kazmaier, A. Brauer, M. Quintel, F. A. Schoendube, and H. Dorge Cardiopulmonary and Systemic Effects of Methylprednisolone in Patients Undergoing Cardiac Surgery Ann. Thorac. Surg., July 1, 2007; 84(1): 110 - 119. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Adabag, T. Rector, S. Mithani, J. Harmala, H. B. Ward, R. F. Kelly, J. T. Nguyen, E. O. McFalls, and H. E. Bloomfield Prognostic Significance of Elevated Cardiac Troponin I After Heart Surgery Ann. Thorac. Surg., May 1, 2007; 83(5): 1744 - 1750. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Mildh, V. Pettila, H. I. Sairanen, and P. H. Rautiainen Cardiac Troponin T Levels for Risk Stratification in Pediatric Open Heart Surgery Ann. Thorac. Surg., November 1, 2006; 82(5): 1643 - 1648. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Croal, G. S. Hillis, P. H. Gibson, M. T. Fazal, H. El-Shafei, G. Gibson, R. R. Jeffrey, K. G. Buchan, D. West, and B. H. Cuthbertson Relationship Between Postoperative Cardiac Troponin I Levels and Outcome of Cardiac Surgery Circulation, October 3, 2006; 114(14): 1468 - 1475. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-S. Wong, A. Asmat, Y.-H. Chan, and C.-N. Lee A randomized, double-blind, placebo-controlled trial of a COX-2 inhibitor (Rofecoxib) in patients undergoing coronary artery bypass surgery Interactive CardioVascular and Thoracic Surgery, April 1, 2006; 5(2): 101 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thielmann, P. Massoudy, M. Neuhauser, S. Knipp, M. Kamler, J. Piotrowski, K. Mann, and H. Jakob Prognostic Value of Preoperative Cardiac Troponin I in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Chest, November 1, 2005; 128(5): 3526 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Bulow, C Klein, I Kuehn, R Hollweck, S G Nekolla, K Schreiber, F Haas, J Bohm, B Schnackenburg, R Lange, et al. Cardiac magnetic resonance imaging: long term reproducibility of the late enhancement signal in patients with chronic coronary artery disease Heart, September 1, 2005; 91(9): 1158 - 1163. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zangrillo, G. Crescenzi, G. Landoni, S. Benussi, M. Crivellari, F. Pappalardo, E. Dorigo, C. Pappone, and O. Alfieri The Effect of Concomitant Radiofrequency Ablation and Surgical Technique (Repair Versus Replacement) on Release of Cardiac Biomarkers During Mitral Valve Surgery Anesth. Analg., July 1, 2005; 101(1): 24 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Garcia, K. Julier, L. Bestmann, A. Zollinger, L. K. von Segesser, T. Pasch, D. R. Spahn, and M. Zaugg Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery Br. J. Anaesth., February 1, 2005; 94(2): 159 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Steuer, T. Bjerner, O. Duvernoy, L. Jideus, L. Johansson, H. Ahlstrom, E. Stahle, and B. Lindahl Visualisation and quantification of peri-operative myocardial infarction after coronary artery bypass surgery with contrast-enhanced magnetic resonance imaging Eur. Heart J., August 1, 2004; 25(15): 1293 - 1299. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Nathan, L. Parlea, J.-Y. Dupuis, P. Hendry, K. A. Williams, F. D. Rubens, and G. A. Wells Safety of deliberate intraoperative and postoperative hypothermia for patients undergoing coronary artery surgery: A randomized trial J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1270 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Januzzi, T. E. MacGillivray, K. Lewandrowski, and E. Lee-Lewandrowski Comparison of tropanin T and creatine kinase-MB fraction in evaluating cardiac patients postoperatively: Reply J. Am. Coll. Cardiol., March 19, 2003; 41(6): 1065 - 1066. [Full Text] [PDF] |
||||
![]() |
C. Chen-Scarabelli and T. Scarabelli Comparison of troponin T and creatine Kinase-MB fraction in evaluating cardiac patients postoperatively J. Am. Coll. Cardiol., March 19, 2003; 41(6): 1065 - 1065. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |